LCZ696 reduced high-sensitivity troponin T by 14% at 36 weeks compared with valsartan (P=0.03) in patients with heart failure with preserved ejection fraction.
RCT (n=298)
Does LCZ696 reduce hs-TnT levels compared to valsartan in patients with heart failure with preserved ejection fraction?
In patients with HFpEF, treatment with LCZ696 significantly reduced hs-TnT levels compared to valsartan, suggesting a reduction in myocardial injury.
Effect estimate: 14% reduction
p-value: p=0.03
BACKGROUND: Elevated high-sensitivity troponin is associated with increasing disease severity in patients with stable heart failure with reduced ejection fraction, but less is known about the association in heart failure with preserved ejection fraction. METHODS AND RESULTS: We examined the prevalence of elevated high-sensitivity troponin T (hs-TnT) in 298 patients with heart failure with preserved ejection fraction enrolled in the Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced markers of heart failure severity compared with valsartan. We assessed the association between hs-TnT and cardiac structure and function, and the effect of LCZ696, compared with valsartan, on hs-TnT over 36 weeks. Elevated hs-TnT in the myocardial injury range (>0.014 μg/L) was found in 55% of patients and was associated with older age, history of diabetes mellitus, higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular filtration rate, and larger left atrial size, left ventricular volume, and mass. LCZ696 treatment reduced hs-TnT to a greater extent at 12 weeks (12% reduction; P=0.05) and at 36 weeks (14% reduction; P=0.03) compared with valsartan. CONCLUSIONS: Troponin T was elevated in a substantial number of patients enrolled in a heart failure with preserved ejection fraction clinical trial and was associated with abnormalities of cardiac structure, function, and elevated baseline N-terminal pro-brain natriuretic peptide. Decreases in hs-TnT with LCZ696 in parallel with improvement in N-terminal pro-brain natriuretic peptide and left atrial size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may reduce this measure of myocardial injury in heart failure with preserved ejection fraction. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00887588.
Jhund et al. (2014) conducted an RCT in heart failure with preserved ejection fraction (n=298). LCZ696 vs. valsartan was evaluated on Reduction in high-sensitivity troponin T at 36 weeks (14% reduction, p=0.03). LCZ696 reduced high-sensitivity troponin T by 14% at 36 weeks compared with valsartan (P=0.03) in patients with heart failure with preserved ejection fraction.